NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered LivesGlobeNewsWire · Oct 15, 2026
Reviewing NeurAxis (NASDAQ:NRXS) and NovoCure (NASDAQ:NVCR)Defense World · Oct 12, 2026
Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)Defense World · Oct 5, 2026
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial OfficerGlobeNewsWire · Sep 29, 2026
Financial Review: NeurAxis (NASDAQ:NRXS) & MariMed (OTCMKTS:MRMD)Defense World · Sep 21, 2026
NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered LivesGlobeNewsWire · Sep 16, 2026NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.32 | -$0.19 | Beat |
| May 12, 2026 | -$0.19 | -$0.18 | Beat |
| Mar 19, 2026 | -$0.22 | -$0.17 | Beat |
| Nov 10, 2025 | -$0.20 | -$0.24 | Miss |
| Aug 12, 2025 | -$0.19 | -$0.22 | Miss |
| May 12, 2025 | -$0.24 | -$0.31 | Miss |